Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group. Ono T, et al. Among authors: emi n. Cancer Sci. 2014 Jan;105(1):97-104. doi: 10.1111/cas.12319. Epub 2014 Jan 9. Cancer Sci. 2014. PMID: 24206578 Free PMC article. Clinical Trial.
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S, et al. Among authors: emi n. Cancer. 2005 Dec 15;104(12):2726-34. doi: 10.1002/cncr.21493. Cancer. 2005. PMID: 16284985 Free article. Clinical Trial.
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.
Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K, Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: emi n. Cancer. 2013 Sep 15;119(18):3326-33. doi: 10.1002/cncr.28212. Epub 2013 Jun 24. Cancer. 2013. PMID: 23798329 Free article. Clinical Trial.
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T. Suzuki T, et al. Among authors: emi n. Blood. 2005 Oct 15;106(8):2854-61. doi: 10.1182/blood-2005-04-1733. Epub 2005 Jun 30. Blood. 2005. PMID: 15994285 Free article.
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. Sakamaki H, et al. Among authors: emi n. Int J Hematol. 2010 Mar;91(2):284-92. doi: 10.1007/s12185-009-0483-2. Int J Hematol. 2010. PMID: 20063133 Clinical Trial.
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.
Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: emi n. Blood. 2013 Apr 18;121(16):3095-102. doi: 10.1182/blood-2012-11-466862. Epub 2013 Feb 14. Blood. 2013. PMID: 23412094 Free article. Clinical Trial.
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.
Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T. Shinagawa K, et al. Among authors: emi n. J Clin Oncol. 2014 Nov 20;32(33):3729-35. doi: 10.1200/JCO.2013.53.3570. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245439 Clinical Trial.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: emi n. J Clin Oncol. 2006 Jan 20;24(3):460-6. doi: 10.1200/JCO.2005.03.2177. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344315 Clinical Trial.
220 results